Nuo Therapeutics, Inc.

What they do

Nuo markets the Aurix System, a point-of-care device that processes a small draw of a patient's peripheral blood into an autologous platelet-rich plasma (PRP) hematogel applied to chronic wounds. The system received FDA 510(k) clearance in 2007 and is one of three platelet-derived products cleared for chronic wound care. After a 2019 furlough and 2021 CMS National Coverage Determination for autologous PRP, the company restarted operations in October 2021 from Houston, Texas.

Revenue drivers

• Aurix branded product — Direct sales of the Aurix System and its disposable components; management said Aurix branded revenues rose more than 30% sequentially in Q2 2026, making it the primary revenue line.
• Private label Aurix (Smith+Nephew) — A distribution agreement under which Smith+Nephew sells a private label version of Aurix; the company reported it confirmed a reimbursement fee milestone under that agreement and expects payment this quarter.
• Medicare reimbursement environment — Revenue depends on CMS coverage; the April 2021 NCD for autologous PRP restarted the business, and proposed 2027 Medicare PFS and OPPS rules, if finalized as proposed, would support stable or increasing payment amounts.

Recent performance

Total revenues were approximately $1.77 million for Q2 2026 and $3.07 million for the first half of 2026, each up more than 150% versus the comparable 2025 periods. Q2 product revenues rose 38% sequentially over Q1 2026, with Aurix branded product revenue up more than 30% sequentially. The Q2 2026 net operating loss of approximately $167,000 improved by roughly $280,000 versus Q1 2026. Full-year 2025 revenue was $3.3 million with a net loss of approximately $2.5 million, and operating cash flow was negative $865,000. At June 30, 2026, cash was $449,325, total assets were $2.6 million, total liabilities were $4.2 million, and stockholders' equity was negative $1.5 million.

Strategy

The company's stated priority is growing Aurix adoption through the improved Medicare reimbursement landscape and the Smith+Nephew private label distribution arrangement, which reached roughly its one-year anniversary of market entry. Management amended and restated its January loan agreement in May 2026, adding $675,000 of interim funding with $325,000 remaining available under commitments totaling $2 million, and retains a company option to increase total borrowings on September 30, 2026. The loan is described as working capital to fund growth and move the company toward breakeven operations. Management also flagged a binding notification and negotiation right granted to Smith+Nephew as a constraint on licensing or business combination options.

Risks

• Single-product concentration — Revenue depends entirely on Aurix and the Smith+Nephew private label, and the company incurred a net loss of about $2.5 million in 2025.
• Going concern and financing need — With $449,325 of cash at June 30, 2026 against $4.2 million of liabilities and negative equity of $1.5 million, the company states it may need additional financing on satisfactory terms or at all.
• Reimbursement dependence — Sales depend on Medicare coverage and payment rates for autologous PRP, and the 2027 rules cited by management are only proposed, not final.
• Dilution and counterparty reliance — The company cites the dilutive impact of raising additional equity or debt, reliance on several single-source suppliers, and its dependence on Smith+Nephew to market and sell the private label product.

Outlook

Management points to proposed Medicare PFS and OPPS rules for January 1, 2027 that, if finalized as proposed, would support stable or increasing Medicare payment amounts for autologous PRP therapies. The company also expects to receive the reimbursement fee milestone payment under the Smith+Nephew agreement in the current quarter and describes the loan as designed to fund growth toward breakeven operations. It cautions that these are forward-looking statements subject to risks and uncertainties.